Creo Medical (GB:CREO) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Creo Medical Group PLC has announced the appointment of Kevin Crofton and Brent Boucher as new independent Non-Executive Directors, with Crofton succeeding Charles Spicer as Chair, effective from July 1, 2024. The change comes as the company, known for its minimally invasive surgical endoscopy devices, transitions towards a new phase of commercial growth. The new directors bring a wealth of experience, with Crofton having a strong track record in the technology sector and Boucher in medical device commercialization.
For further insights into GB:CREO stock, check out TipRanks’ Stock Analysis page.